JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
In November 2025, Intellia announced that in the MAGNITUDE trial (NCT06128629) of nexiguran ziclumeran, an in vivo CRISPR therapy, for transthyretin (ATTR) amyloidosis, a male patient in his 80s died after receiving the study drug. The therapy is being developed in partnership with Regeneron. Speaking at the JP Morgan Healthcare Conference 2026, Intellia CEO John Leonard said that the patient attended the emergency room due to abdominal pain, where tests revealed elevated transaminase. During his stay in the hospital, it was revealed that the patient had air in his abdomen and received surgery where a perforation and ulcer were found. The patient died following a case of sepsis. The update on the circumstances of the patient's death may provide investors with more confidence in the safety of the gene therapy, especially given liver-associated patient deaths in gene therapy studies by other companies, including Sarepta and Pfizer Leonard said that the company has three ongoing
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Is Regeneron (REGN) Offering Value After Recent Share Price Swings? [Yahoo! Finance]Yahoo! Finance
- BioNTech (BNTX) Valuation Check As Shares Rebound Despite Longer Term Return Weakness [Yahoo! Finance]Yahoo! Finance
- AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions [Yahoo! Finance]Yahoo! Finance
- Regeneron CEO: AI is as good as the data it can train on [CNBC]CNBC
- 1 Mooning Stock with Exciting Potential and 2 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 10/28/25 - Beat
REGN
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 4
- 1/7/26 - Form 144
- REGN's page on the SEC website